Proxy Statement - Other Information (preliminary) (pre 14c)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14C INFORMATION
Information Statement Pursuant to Section 14(c)
of the Securities Exchange Act of 1934
Check the appropriate box:
x
Preliminary Information Statement
o
Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2))
o
Definitive Information Statement
BRAVATEK SOLUTIONS, INC.
(Name of Registrant as Specified in Charter)
Payment of Filing Fee (Check the appropriate box):
x
No fee required.
o
Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11.
1)
Title of each class of securities to which transaction applies:
2)
Aggregate number of securities to which transaction applies:
3)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
4)
Proposed maximum aggregate value of transaction:
5)
Total fee paid:
o
Fee paid previously with preliminary materials.
o
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
1)
Amount Previously Paid:
2)
Form, Schedule or Registration Statement No:
3)
Filing Party:
4)
Date Filed:
Bravatek Solutions, Inc.
2028 E. Ben White Boulevard
Suite 240-2835
Austin, TX 78741
866-204-6703
June __, 2018
NOTICE OF STOCKHOLDER ACTION BY WRITTEN CONSENT
Dear Shareholder:
This notice and the accompanying Information Statement are being distributed to the holders of record (the “ Shareholders ”) of the voting capital stock of Bravatek Solutions, Inc., a Colorado corporation (the “ Company ”), as of the close of business on June 1, 2018 (the “ Record Date ”), in accordance with Rule 14c-2 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”) and the notice requirements of the Colorado Business Corporation Act (the “ CBCA ”). The purpose of this notice and the accompanying Information Statement is to notify the Shareholders of actions approved by our Board of Directors (the “ Board ”) and taken by written consent in lieu of a meeting by the holders of a majority of the voting power of our outstanding capital stock as of the Record Date (the “ Written Consent ”).
The Written Consent approved the following actions:
Increasing the number of authorized shares of Common Stock from 10,000,000,000 shares to 10,600,000,000 shares initially, with the Board having discretion to increase the number of authorized shares by an additional 1,000,000,000 thereafter at any time in the future in the Board’s sole discretion (the “ Authorized Share Increase ”).
The Written Consent is the only shareholder approval required to effect the Corporate Actions under the CBCA, our Articles of Incorporation, as amended, or our Bylaws. No consent or proxies are being requested from our shareholders, and our Board is not soliciting your consent or proxy in connection with the Corporate Actions. The Corporate Actions, as approved by the Written Consent, will not become effective until 20 calendar days after the accompanying Information Statement is first mailed or otherwise delivered to the Shareholders. We expect to mail the accompanying Information Statement to the Shareholders on or about June __, 2018.
Important Notice Regarding the Availability of Information Statement Materials in Connection with this Schedule 14C : We will furnish a copy of this Notice and Information Statement, without charge, to any shareholder upon written request to the address set forth above, Attention: Corporate Secretary.
WE ARE NOT ASKING YOU FOR A PROXY, AND YOU ARE REQUESTED NOT TO SEND US A PROXY.
Sincerely,
/s/ Thomas A. Cellucci
Thomas A. Cellucci, PhD, MBA
Chairman & Chief Executive Officer
Bravatek Solutions, Inc.
2028 E. Ben White Boulevard
Suite 240-2835
Austin, TX 78741
866-204-6703
______________
INFORMATION
STATEMENT
(Preliminary)
_____________
WE ARE NOT ASKING YOU FOR A PROXY, AND YOU ARE REQUESTED NOT TO SEND A PROXY.
INTRODUCTION
This Information Statement advises the shareholders of Bravatek Solutions, Inc. (the “ Company ,” “ we ,” “ our ” or “ us ”) of the approval of the following corporate actions (the “ Corporate Actions ”):
Increasing the number of authorized shares of Common Stock from 10,000,000,000 shares to 10,600,000,000 shares initially, with the Company’s Board of Directors (the “ Board ”) having discretion to increase the number of authorized shares by an additional 1,000,000,000 thereafter at any time in the future in the Board’s sole discretion (the “ Authorized Share Increase ”).
On June 1, 2018 (the “ Record Date ”), our Board of Directors (the “ Board ”) approved the Corporate Actions and submitted the same to certain holders of our Series C Preferred Stock and Series E Preferred Stock. On the same date, the holder of a majority of the voting power of the outstanding capital stock of the Company (the “ Majority Stockholder ”) executed and delivered to us a written consent in lieu of a meeting (the “ Written Consent ”) approving the Corporate Actions.
Section 7-107-104 of the CBCA provides that the written consent of the holders of outstanding shares of voting capital stock having not less than the minimum number of votes which would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted can approve an action in lieu of conducting a special stockholders’ meeting convened for the specific purpose of such action. Section 7-107-104 of the CBCA, however, requires that in the event an action is approved by written consent, a company must provide notice of the taking of any corporate action without a meeting to all shareholders who were entitled to vote upon the action but who have not consented to the action. Under Colorado law, shareholders are not entitled to dissenters’ rights with respect to the Corporate Actions (the “ Stockholders ”).
In accordance with the foregoing, we intend to mail a notice of Written Consent and this Information Statement on or about June __, 2018. This Information Statement contains a brief summary of the material aspects of the actions approved by the Board and the Majority Stockholder, which holds a majority of the voting capital stock of the Company.
read in full
https://ih.advfn.com/p.php?pid=nmona&article=77598661
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14C INFORMATION
Information Statement Pursuant to Section 14(c)
of the Securities Exchange Act of 1934
Check the appropriate box:
x
Preliminary Information Statement
o
Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2))
o
Definitive Information Statement
BRAVATEK SOLUTIONS, INC.
(Name of Registrant as Specified in Charter)
Payment of Filing Fee (Check the appropriate box):
x
No fee required.
o
Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11.
1)
Title of each class of securities to which transaction applies:
2)
Aggregate number of securities to which transaction applies:
3)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
4)
Proposed maximum aggregate value of transaction:
5)
Total fee paid:
o
Fee paid previously with preliminary materials.
o
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
1)
Amount Previously Paid:
2)
Form, Schedule or Registration Statement No:
3)
Filing Party:
4)
Date Filed:
Bravatek Solutions, Inc.
2028 E. Ben White Boulevard
Suite 240-2835
Austin, TX 78741
866-204-6703
June __, 2018
NOTICE OF STOCKHOLDER ACTION BY WRITTEN CONSENT
Dear Shareholder:
This notice and the accompanying Information Statement are being distributed to the holders of record (the “ Shareholders ”) of the voting capital stock of Bravatek Solutions, Inc., a Colorado corporation (the “ Company ”), as of the close of business on June 1, 2018 (the “ Record Date ”), in accordance with Rule 14c-2 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”) and the notice requirements of the Colorado Business Corporation Act (the “ CBCA ”). The purpose of this notice and the accompanying Information Statement is to notify the Shareholders of actions approved by our Board of Directors (the “ Board ”) and taken by written consent in lieu of a meeting by the holders of a majority of the voting power of our outstanding capital stock as of the Record Date (the “ Written Consent ”).
The Written Consent approved the following actions:
Increasing the number of authorized shares of Common Stock from 10,000,000,000 shares to 10,600,000,000 shares initially, with the Board having discretion to increase the number of authorized shares by an additional 1,000,000,000 thereafter at any time in the future in the Board’s sole discretion (the “ Authorized Share Increase ”).
The Written Consent is the only shareholder approval required to effect the Corporate Actions under the CBCA, our Articles of Incorporation, as amended, or our Bylaws. No consent or proxies are being requested from our shareholders, and our Board is not soliciting your consent or proxy in connection with the Corporate Actions. The Corporate Actions, as approved by the Written Consent, will not become effective until 20 calendar days after the accompanying Information Statement is first mailed or otherwise delivered to the Shareholders. We expect to mail the accompanying Information Statement to the Shareholders on or about June __, 2018.
Important Notice Regarding the Availability of Information Statement Materials in Connection with this Schedule 14C : We will furnish a copy of this Notice and Information Statement, without charge, to any shareholder upon written request to the address set forth above, Attention: Corporate Secretary.
WE ARE NOT ASKING YOU FOR A PROXY, AND YOU ARE REQUESTED NOT TO SEND US A PROXY.
Sincerely,
/s/ Thomas A. Cellucci
Thomas A. Cellucci, PhD, MBA
Chairman & Chief Executive Officer
Bravatek Solutions, Inc.
2028 E. Ben White Boulevard
Suite 240-2835
Austin, TX 78741
866-204-6703
______________
INFORMATION
STATEMENT
(Preliminary)
_____________
WE ARE NOT ASKING YOU FOR A PROXY, AND YOU ARE REQUESTED NOT TO SEND A PROXY.
INTRODUCTION
This Information Statement advises the shareholders of Bravatek Solutions, Inc. (the “ Company ,” “ we ,” “ our ” or “ us ”) of the approval of the following corporate actions (the “ Corporate Actions ”):
Increasing the number of authorized shares of Common Stock from 10,000,000,000 shares to 10,600,000,000 shares initially, with the Company’s Board of Directors (the “ Board ”) having discretion to increase the number of authorized shares by an additional 1,000,000,000 thereafter at any time in the future in the Board’s sole discretion (the “ Authorized Share Increase ”).
On June 1, 2018 (the “ Record Date ”), our Board of Directors (the “ Board ”) approved the Corporate Actions and submitted the same to certain holders of our Series C Preferred Stock and Series E Preferred Stock. On the same date, the holder of a majority of the voting power of the outstanding capital stock of the Company (the “ Majority Stockholder ”) executed and delivered to us a written consent in lieu of a meeting (the “ Written Consent ”) approving the Corporate Actions.
Section 7-107-104 of the CBCA provides that the written consent of the holders of outstanding shares of voting capital stock having not less than the minimum number of votes which would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted can approve an action in lieu of conducting a special stockholders’ meeting convened for the specific purpose of such action. Section 7-107-104 of the CBCA, however, requires that in the event an action is approved by written consent, a company must provide notice of the taking of any corporate action without a meeting to all shareholders who were entitled to vote upon the action but who have not consented to the action. Under Colorado law, shareholders are not entitled to dissenters’ rights with respect to the Corporate Actions (the “ Stockholders ”).
In accordance with the foregoing, we intend to mail a notice of Written Consent and this Information Statement on or about June __, 2018. This Information Statement contains a brief summary of the material aspects of the actions approved by the Board and the Majority Stockholder, which holds a majority of the voting capital stock of the Company.
read in full
https://ih.advfn.com/p.php?pid=nmona&article=77598661
